Acoramidis治疗转甲状腺素蛋白淀粉样心肌病的长期疗效持久性:ATTRibute-CM随机临床试验开放标签扩展
该开放标签扩展研究评估Acoramidis治疗转甲状腺素蛋白淀粉样心肌病(ATTR-CM)至第54个月的长期疗效与安全性。持续Acoramidis治疗降低全因死亡、心血管死亡和首次心血管住院风险,且生物标志物、功能 capacity 和健康状况稳定,支持早期持续治疗。
要点
- 持续Acoramidis至第54个月降低全因死亡风险(HR 0.55)和心血管死亡风险(HR 0.51)。
- 持续治疗降低首次心血管住院风险(HR 0.53),各预设亚组一致。
- 第30个月从安慰剂换用Acoramidis后生物标志物和功能 capacity 稳定或改善。
核心结论
- 早期持续Acoramidis治疗至第54个月持续增量降低全因死亡、心血管死亡和首次心血管住院风险。
研究设计与样本
- ATTRibute-CM随机临床试验的开放标签扩展研究,国际多中心、正在进行。
- ATTRibute-CM中632例随机(Acoramidis 421例,安慰剂211例),389例纳入OLE(持续组263例,换用组126例)。
主要发现
- 持续Acoramidis组至第54个月全因死亡HR 0.55(95% CI 0.42-0.74,P < .001)。
- 持续Acoramidis组至第54个月心血管死亡HR 0.51(95% CI 0.36-0.71,P < .001)。
- 持续Acoramidis组至第54个月首次心血管住院HR 0.53(95% CI 0.42-0.69,P < .001)。
- 持续Acoramidis稳定NT-proBNP升高、维持较高sTTR水平、稳定KCCQ-OS评分和6MWD。
- 第30个月换用Acoramidis后NT-proBNP和KCCQ-OS稳定,sTTR和6MWD改善,未发现新长期安全性问题。
临床怎么用
- 对于ATTR-CM患者,早期启动并持续Acoramidis治疗可带来长期生存和住院获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disorder caused by destabilization of serum transthyretin (sTTR). Acoramidis, an approved therapy that achieves near-complete (≥90%) sTTR stabilization, demonstrated clinical benefit through month 30 in ATTRibute-CM, which was incremental through month 42 in the open-label extension (OLE); however, the longer-term durability of outcomes has not been reported. OBJECTIVE: To evaluate the long-term efficacy and safety of acoramidis through month 54. DESIGN, SETTING, AND PARTICIPANTS: This OLE of the ATTRibute-CM randomized clinical trial is an international, multicenter, ongoing OLE study. Data accumulated between October 2021 and April 2025 through month 24 of the OLE (month 54) are reported. Participants (aged 18-90 years) who completed ATTRibute-CM and met the OLE eligibility criteria were invited to enroll in the OLE. Data were analyzed from May 2025 through November 2025. INTERVENTIONS: All OLE participants received open-label oral acoramidis, 800 mg, twice daily. Acoramidis recipients from ATTRibute-CM continued therapy (continuous acoramidis) and placebo recipients switched to acoramidis (placebo to acoramidis). MAIN OUTCOMES AND MEASURES: The primary outcome was time to event for all-cause mortality (ACM), cardiovascular-related mortality (CVM), and first cardiovascular hospitalization (CVH), which was assessed for both groups. Biomarkers of disease progression (N-terminal pro-B-type natriuretic peptide [NT-proBNP]), sTTR, functional capacity (6-minute walk distance [6MWD]), and heart failure-related health status (Kansas City Cardiomyopathy Questionnaire-Overall Summary [KCCQ-OS] score) were analyzed. RESULTS: In ATTRibute-CM, 632 participants were randomized to receive acoramidis (n = 421) or placebo (n = 211); mean (SD) age was 77.3 (6.6) years, and 62 participants (9.8%) were female. Overall, 389 participants enrolled in the OLE (263 in the continuous acoramidis group; 126 in the placebo-to-acoramidis group). Continuous acoramidis treatment reduced risks of ACM (hazard ratio [HR], 0.55; 95% CI, 0.42-0.74; P < .001) and CVM (HR, 0.51; 95% CI, 0.36-0.71; P < .001) through month 54, with consistent efficacy across all prespecified subgroups. Continuous acoramidis reduced time to first CVH (HR, 0.53; 95% CI, 0.42-0.69; P < .001) through month 54. Through month 54, continuous acoramidis stabilized increases in NT-proBNP, sustained higher sTTR levels, and stabilized KCCQ-OS score and 6MWD. Switching from placebo to acoramidis at month 30 was associated with stabilization of NT-proBNP and KCCQ-OS score and improvements in sTTR and 6MWD through month 54. No new long-term safety concerns were identified. CONCLUSIONS AND RELEVANCE: In this OLE of the ATTRibute-CM randomized clinical trial, early and continuous acoramidis treatment resulted in sustained incremental reductions in ACM, CVM, and first CVH through month 54. These findings support the importance of early and continuous long-term treatment with acoramidis in ATTR-CM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04988386.
引用
- Soman P, Cuddy SAM, Gillmore JD, et al. Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41911489. doi:10.1001/jamacardio.2026.0819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。